Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Neurology

Symptoms and Disease Progression

At a Glance

LGMDR1 (calpainopathy) is a progressive muscle disease that typically begins between ages 8 and 15. It selectively weakens pelvic and shoulder muscles, leading to mobility challenges over time. While walking becomes difficult, the heart and brain are usually unaffected.

Understanding the symptoms and typical progression of LGMDR1 (calpainopathy) can help you and your care team prepare for the future. While every individual’s experience is unique, the disease often follows a recognizable pattern of muscle involvement and functional change.

Early Signs and Symptoms

The first symptoms of LGMDR1 typically appear between the ages of 8 and 15, though onset can vary widely from early childhood to late adulthood [1][2].

  • Muscle Pain (Myalgia): Many patients experience muscle pain or cramping, sometimes even before significant weakness is noticed [3].
  • Joint Contractures: A hallmark of early LGMDR1 is the development of contractures—a permanent tightening of muscles, tendons, or skin that prevents normal movement. These often affect the Achilles tendons (leading to toe-walking) and the muscles surrounding the spine [4][5].
  • High CK Levels Without Weakness: Some people are first identified because of high levels of creatine kinase (CK) in their blood, an enzyme that leaks out of damaged muscle, even if they don’t feel weak yet [6][4].

The Pattern of Muscle Weakness

LGMDR1 does not affect all muscles equally. It typically follows a “selective” pattern, where certain muscle groups are targeted early while others remain strong for much longer [5][7].

Early/Severely Affected Muscles Relatively Spared Muscles
Hip Adductors: Muscles that pull your legs together [5]. Sartorius: A long, thin muscle running down the thigh [8].
Hamstrings: Specifically the biceps femoris (back of the thigh) [7][9]. Gracilis: A muscle on the inner thigh [8].
Gluteus Maximus: The main muscle of the buttocks used for standing up [10]. Extensor Digitorum Longus: A muscle in the lower leg that lifts the toes [7].
Spine Extensors: Muscles that keep your back straight [5].

This specific pattern of weakness often leads to a waddling gait or an increased curve in the lower back, known as lordosis [5][11].

Typical Disease Progression

LGMDR1 is generally described as a slowly progressive condition. While the speed of progression varies, researchers have identified common milestones based on the number of years since the first symptoms appeared.

  • Years 1–10: Weakness usually begins in the pelvic girdle, making it harder to run, climb stairs, or rise from a squatting position. Shoulder girdle weakness may also begin, affecting the ability to lift heavy objects overhead [3][12].
  • Years 10–25: Over this period, walking often becomes more difficult. Many patients may begin using mobility aids, such as canes or walkers. Research indicates that after approximately 25 years of disease progression, many patients will need to transition to a scooter or wheelchair full-time [13].
  • Long-term Outlook: The timeline for losing the ability to walk (ambulation) is highly variable. Some individuals may require a wheelchair in their 20s or 30s, while others remain ambulatory well into late adulthood [1][2].

Managing Fatigue

Beyond mechanical weakness, many patients experience generalized daily fatigue. Because your weakened muscles have to work significantly harder to perform the same tasks as healthy muscles, your overall energy reserves can drain quickly. Using mobility aids strategically—even when you can still walk—is an effective way to conserve energy and manage this fatigue.

Throughout this journey, it is important to remember that while the limb muscles weaken, the heart and brain are typically not affected [14][15]. Continuous monitoring of respiratory function remains vital, as the muscles that support breathing can be affected even while a patient is still able to walk [14].

Common questions in this guide

What are the first signs of LGMDR1?
Early signs often appear between ages 8 and 15. Common initial symptoms include muscle pain, high creatine kinase (CK) levels in the blood, and joint contractures, such as tightening of the Achilles tendons that can cause toe-walking.
How does LGMDR1 affect walking and mobility?
LGMDR1 usually starts by weakening the pelvic muscles, hamstrings, and lower back, which can cause a waddling walk or an arched lower back. As the disease progresses over 10 to 25 years, walking often becomes more difficult, and many people begin using canes, walkers, or wheelchairs.
Does LGMDR1 cause heart or brain problems?
No, the heart and brain are typically spared in LGMDR1. However, the muscles that support breathing can weaken over time, so regular monitoring of your respiratory function is important.
Why do I experience so much fatigue with LGMDR1?
Weakened muscles have to work much harder than healthy muscles to perform the same everyday tasks. This extra effort drains your energy reserves quickly, making strategic use of mobility aids an effective way to manage daily fatigue.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which of my muscles currently show the most weakness, and which ones are still strong?
  2. 2.Should I have an MRI of my muscles to help track how my condition is progressing over time?
  3. 3.What are the early signs that my respiratory (breathing) muscles might be weakening, and how often should we test them?
  4. 4.Are there specific exercises I should avoid to prevent 'overwork weakness' or muscle pain?
  5. 5.Can you help me monitor for joint contractures, and what stretches should I be doing daily?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (15)
  1. 1

    A rare case of late-onset limb-girdle muscular dystrophy: Calpainopathy.

    Painkra B, Mallick R, Das S, et al.

    Aging medicine (Milton (N.S.W)) 2022; (5(3)):237-240 doi:10.1002/agm2.12219.

    PMID: 36247336
  2. 2

    A novel CAPN3 mutation in late-onset limb-girdle muscular dystrophy with early respiratory insufficiency.

    Martinez-Thompson JM, Moore SA, Liewluck T

    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2018; (53()):229-231 doi:10.1016/j.jocn.2018.04.025.

    PMID: 29685414
  3. 3

    Natural history of LGMD2A for delineating outcome measures in clinical trials.

    Richard I, Hogrel JY, Stockholm D, et al.

    Annals of clinical and translational neurology 2016; (3(4)):248-65 doi:10.1002/acn3.287.

    PMID: 27081656
  4. 4

    Clinical and Pathological Heterogeneity of Korean Patients with CAPN3 Mutations.

    Park HJ, Jang H, Lee JH, et al.

    Yonsei medical journal 2016; (57(1)):173-9 doi:10.3349/ymj.2016.57.1.173.

    PMID: 26632398
  5. 5

    European muscle MRI study in limb girdle muscular dystrophy type R1/2A (LGMDR1/LGMD2A).

    Barp A, Laforet P, Bello L, et al.

    Journal of neurology 2020; (267(1)):45-56 doi:10.1007/s00415-019-09539-y.

    PMID: 31555977
  6. 6

    Mutational Spectrum of CAPN3 with Genotype-Phenotype Correlations in Limb Girdle Muscular Dystrophy Type 2A/R1 (LGMD2A/LGMDR1) Patients in India.

    Pathak P, Sharma MC, Jha P, et al.

    Journal of neuromuscular diseases 2021; (8(1)):125-136 doi:10.3233/JND-200547.

    PMID: 33337384
  7. 7

    Fatty infiltration evaluation and selective pattern characterization of lower limbs in limb-girdle muscular dystrophy type 2A by muscle magnetic resonance imaging.

    Feng X, Luo S, Li J, et al.

    Muscle & nerve 2018; (58(4)):536-541 doi:10.1002/mus.26169.

    PMID: 29797799
  8. 8

    Muscle MRI characteristic pattern for late-onset TK2 deficiency diagnosis.

    Domínguez-González C, Fernández-Torrón R, Moore U, et al.

    Journal of neurology 2022; (269(7)):3550-3562 doi:10.1007/s00415-021-10957-0.

    PMID: 35286480
  9. 9

    Regional variation of thigh muscle fat infiltration in patients with neuromuscular diseases compared to healthy controls.

    Greve T, Burian E, Zoffl A, et al.

    Quantitative imaging in medicine and surgery 2021; (11(6)):2610-2621 doi:10.21037/qims-20-1098.

    PMID: 34079727
  10. 10

    Value of muscle magnetic resonance imaging in the differential diagnosis of muscular dystrophies related to the dystrophin-glycoprotein complex.

    Xie Z, Xie Z, Yu M, et al.

    Orphanet journal of rare diseases 2019; (14(1)):250 doi:10.1186/s13023-019-1242-y.

    PMID: 31747956
  11. 11

    Whole-Body MRI in Limb Girdle Muscular Dystrophy Type R1/2A: Correlation With Clinical Scores.

    Aivazoglou LU, Guimarães JB, Costa MAF, et al.

    Muscle & nerve 2022; (66(4)):471-478 doi:10.1002/mus.27686.

    PMID: 35894554
  12. 12

    Dystrophinopathies and Limb-Girdle Muscular Dystrophies.

    Domingos J, Sarkozy A, Scoto M, Muntoni F

    Neuropediatrics 2017; (48(4)):262-272 doi:10.1055/s-0037-1601860.

    PMID: 28427100
  13. 13

    Over three decades of natural history of limb girdle muscular dystrophy type R1/2A and R2/2B: Mathematical modelling of a multifactorial study.

    LoMauro A, Gandossini S, Russo A, et al.

    Neuromuscular disorders : NMD 2021; (31(6)):489-497 doi:10.1016/j.nmd.2021.02.018.

    PMID: 33836912
  14. 14

    Cardiopulmonary dysfunction in patients with limb-girdle muscular dystrophy 2A.

    Mori-Yoshimura M, Segawa K, Minami N, et al.

    Muscle & nerve 2017; (55(4)):465-469 doi:10.1002/mus.25369.

    PMID: 27500519
  15. 15

    Limb Girdle Muscular Dystrophies.

    Bockhorst J, Wicklund M

    Neurologic clinics 2020; (38(3)):493-504 doi:10.1016/j.ncl.2020.03.009.

    PMID: 32703463

This page provides general information about LGMDR1 symptoms and disease progression. Always consult your neuromuscular specialist for medical advice tailored to your specific situation.

Get notified when new evidence is published on Calpain-3-related limb-girdle muscular dystrophy R1.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.